Ankylosing spondylitis trials in Poland

In Poland 9 Also abroad 89

9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Bydgoszcz, Cracow, Lublin, Torun, Warsaw
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
Phase 1Taking people
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Where
Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nowa Sól, Olsztyn, Płońsk, Poznan, Torun, Warsaw, Wroclaw
Age
18 years and over
People
392 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07290036
Phase 3Taking people
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Where
Cracow, Sosnowiec
Age
2 years to 18 years
People
40 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06668181 · EU 2023-508845-41-00
Phase 2Taking people
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Where
Bydgoszcz, Lublin, Torun, Warsaw
Age
18 years to 80 years
People
315 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07133633 · EU 2025-521059-21-00
Phase 1Taking people
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
Where
Lublin, Poznan
Age
18 years and over
People
86 worldwide
Run by
Grey Wolf Therapeutics Limited
See details and how to join2025-521315-39-00 · EU 2025-521315-39-00
Phase 1/2Taking people
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
Where
Krakow, Lublin, Poznan
Age
18 years to 65 years
People
140 worldwide
Run by
Grey Wolf Therapeutics
See details and how to joinNCT07047703
Phase 2/3Taking people
Study of the efficacy and safety of etanercept treatment in patients with SAPHO syndrome
Where
Olsztyn, Szczecin, Warsaw
Age
18 years and over
People
60
Run by
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
See details and how to join2024-516919-25-00 · EU 2024-516919-25-00
Phase 4Taking people
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Where
Bydgoszcz, Bytom, Elblag, Krakow, Kraków, Lublin, Poznan, Warsaw, Warszawa, Wroclaw
Age
18 years and over
People
100 worldwide
Run by
CARE ARTHRITIS LTD.
See details and how to joinNCT06454188 · EU 2023-510242-24-00
Phase 4Not yet taking people in Poland
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
Where
Krakow, Lublin, Warsaw
Age
18 years and over
People
200 worldwide
Run by
CARE ARTHRITIS LTD.
See details and how to joinNCT07018206 · EU 2025-522118-21-00